News
BOYDSense (an Alpha MOS subsidiary), selected among the 12 most innovative French Medtech by the National Union of the Medical Technology Industry (SNITEM)
--BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN : FR0013421286 ALNEO), has been selected by a jury from the National Union of the Medical Technology Industry (SNITEM) in ordert o participate to the 8th edition of the start-ups day, organized on April 4th at la Cité des Sciences. This event brings together all start-ups […]
News
BOYDSense awarded by the DCB Innovation Challenge 2022 Expert Jury
--BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), announces that they have been recognized and awarded in the category “diabetes devices” from the DCB Innovation Challenge 2022. Held every year, the DCB Open Innovation Challenge aims at fostering new initiatives and innovative projects in the domain of diabetes management.BOYDSense breath-based glucose monitoring […]
News
From 38 Finalists. RESI Boston’s Audience Selects Innovation Challenge Champions
--Boston, Mass. – September 12, 2019 – The RESI Innovation Challenge showcased 38 emerging startups in the biotech, medtech, diagnostics and digital health fields.  All the competitors brought novel, exciting discoveries to the technology showcase […]